Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

Benzinga · 3d ago
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.